Tiziana Life Sciences PLC Dr Howard Weiner on Bloomberg at 1.50pm ET today
30 Juin 2021 - 12:36PM
RNS Non-Regulatory
TIDMTILS
Tiziana Life Sciences PLC
30 June 2021
Dr Howard Weiner, Chairman of the Tiziana Scientific Advisory
Board, to give an interview on Bloomberg Markets at 1.50pm ET
today.
NEW YORK & LONDON , June 30, 2021 - Tiziana Life Sciences
plc (NASDAQ: TLSA, LSE: TILS ), a biotechnology company focused on
innovative therapeutics for oncology, inflammation and infectious
diseases, announces an interview with the Chairman of its'
Scientific Advisory Board and Professor of Neurology at Harvard
Medical School, Dr Howard Weiner is to air on Bloomberg Markets
with Matt Miller and Amanda Lang today at 1.50pm ET/6.50pm BST.
About Tiziana Life Sciences
Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) is a UK
biotechnology company that focuses on the discovery and development
of novel molecules to treat human disease in oncology and
immunology. In addition to Milciclib (a CDK inhibitor being
developed in oncology), the Company is also developing Foralumab in
COVID-19, multiple sclerosis, and Crohn's Disease. Foralumab is the
only second generation fully human anti-CD3 monoclonal antibody in
clinical development in the world. This Phase 2 compound has
potential application in a wide range of autoimmune and
inflammatory diseases, such as nonalcoholic steatohepatitis (NASH),
ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D),
Crohn's disease, psoriasis and rheumatoid arthritis, where
modulation of a T-cell response is desirable. The Company is
accelerating development of anti-Interleukin 6 receptor (IL6R) mAb,
a fully human monoclonal antibody for treatment of IL6-induced
inflammatory pulmonary diseases.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements. These forward-looking statements are not historical
facts but rather are based on the Company's current expectations,
estimates, and projections about its industry; its beliefs; and
assumptions. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company's control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements.
The Company cautions security holders and prospective security
holders not to place undue reliance on these forward-looking
statements, which reflect the view of the Company only as of the
date of this announcement. The forward-looking statements made in
this announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances, or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority.
For further enquiries:
United Kingdom:
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder
+44 (0)20 7495 2379
United States:
Investors:
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
dave@redchip.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAWPUAWQUPGGUU
(END) Dow Jones Newswires
June 30, 2021 06:36 ET (10:36 GMT)
Tiziana Life Sciences (LSE:TILS)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Tiziana Life Sciences (LSE:TILS)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024